Clinical Trial Update: Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib malate in patients with non-clear cell renal cell carcinoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Cancer, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-05-04